Treatment of Light Chain Deposition Disease Using Bortezomib-Based Regimen Followed by Thalidomide-Based Regimen in a Saudi Male
Light chain deposition disease (LCDD) is a rare illness with, as yet, no clear evidence-based guidelines for its treatment. To the best of our knowledge, LCDD has not been previously reported from Saudi Arabia. We present in this report, a 38-year-old Saudi male who presented with clinical features...
Main Authors: | Bappa Adamu, Mushabab Al-Ghamdi, Mustafa Ahmad, Khaled O. Alsaad |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2016-01-01
|
Series: | Case Reports in Nephrology |
Online Access: | http://dx.doi.org/10.1155/2016/7485695 |
Similar Items
-
The Applicability of the International Staging System in Chinese Patients with Multiple Myeloma Receiving Bortezomib or Thalidomide-Based Regimens as Induction Therapy: A Multicenter Analysis
by: Jing Lu, et al.
Published: (2015-01-01) -
The choice of regimens based on bortezomib for patients with newly diagnosed multiple myeloma.
by: Jingsong He, et al.
Published: (2014-01-01) -
Long-term outcomes of different bortezomib-based regimens in Chinese myeloma patients
by: Wang H, et al.
Published: (2016-01-01) -
Clinical Assessment of Bortezomib for Multiple Myeloma in Comparison with Thalidomide
by: Mitsutoshi Satoh, et al.
Published: (2011-02-01) -
Monoclonal Gammopathy of Renal Significance: Clinical and Histological Efficacy of a Bortezomib-Based Regimen
by: Giacomo Quattrocchio, et al.
Published: (2020-12-01)